Skip to main content
. Author manuscript; available in PMC: 2021 Feb 24.
Published in final edited form as: Clin Pharmacol Ther. 2020 Oct 8;109(1):73–81. doi: 10.1002/cpt.2028

Figure 5.

Figure 5

Interpatient variability in hydroxyurea pharmacokinetics (PKs) and benefits of Bayesian adaptive control. There is significant interpatient variability in hydroxyurea PKs with individual area under the concentration-time curves (AUCs) ranging from 40 to 140 mg*hour/L. Bayesian estimation of AUC for individual patients demonstrates a more accurate estimation of individual hydroxyurea exposure than the population model alone.